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Sir,
We explicitly intend to keep the current response short as
we believe that only reliable, double-blind studies with
good controls can shed light on the serious doubts raised
by us (Schabus et al., 2017) and others (Vollebregt et al.,
2014; Cortese et al., 2016; Thibault and Raz, 2016;
Schonenberg et al., 2017; Thibault et al., 2017, 2018).
In the following we will address the main points raised
by Witte et al. (2018):
(i) Witte and colleagues correctly mention that in our ear-
lier response (Schabus, 2017) we showed ‘an increase in
physical quality-of-life (QoL) ratings across trainings
sessions for real as well as sham NFT’. Witte and col-
leagues criticize that we took this as argument that this
is indicative of a major placebo effect and point to the
‘noisy’ subjective data. We are well aware of the ‘noisy
nature’ of purely questionnaire-derived QoL data as
well as the effect of sample sizes. However, we
wanted to emphasize that purely subjective meas-
ures—which are reported exclusively, i.e. without
‘neural data’ in most neurofeedback (NFT) studies—
will almost always show improvements independent
of whether real NFT or a sham-control is presented.
Given the results of our earlier study, we additionally
speculated that subjects may actually feel more sup-
ported in certain subjective dimensions (here, social
quality of life including social support questions) if
truly double-blind designs are not adopted (Fig. 1,
Schabus, 2017; Schabus et al., 2017). We agree that
the variance in such data is huge and that sample
sizes well above 20–30 participants per group are
highly desired. We are therefore eager to see whether
larger (well controlled) studies will come to different
conclusions.
(ii) Witte et al. bring up the question what a ‘placebo’ is in
the ﬁrst place. According to Price and colleagues (2008)
‘Placebos have typically been identiﬁed as inert agents
or procedures aimed at pleasing the patient rather than
exerting a speciﬁc effect’. According to our understand-
ing, this is exactly what we have reported earlier
(Schabus, 2017; Schabus et al., 2017). We see patients
with (a) increased subjective sleep quality (PSQI) (Fig. 5,
Schabus et al., 2017); and (b) increased QoL (Fig. 1,
Schabus, 2017) but importantly, no speciﬁc NFT effect.
That is, NFT does not (a) bring about larger subjective
improvements than sham feedback; nor (b) does power
in the trained EEG frequency bands change even mi-
nutes after training (Fig. 3, Schabus et al., 2017); or
(c) would NFT lead to changes in sleep architecture
(Table 1, Schabus et al., 2017); or (d) sleep spindles
(Fig. 4, Schabus et al., 2017) during subsequent sleep.
We even agree that patients’ outcome expectations or
the treatment context may contribute more to the out-
come than treatment-speciﬁc effects (Schedlowski et al.,
2015). Yet, it is then ethically questionable whether
such treatment needs high-tech NFT equipment and
justiﬁes expensive ‘neurotherapy’ sessions for the
patients.
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(iii) The last argument addresses what one can actually con-
sider a ‘systematic change’ in EEG-derived parameters
after NFT training. This is without doubt a question
open to discussion, perhaps even a question the NFT
ﬁeld has ignored for too long. Perhaps this is the reason
for the NFT ﬁeld ‘answering’ the question by simply not
reporting EEG parameters at all, but still claiming that
their ‘neurotherapy’ brings about neuronal changes. It
remains difﬁcult to picture how wellbeing or behaviour
should change (due to neural changes) over time if even
the trained frequency bands (here, 12–15Hz) don’t
show any statistically relevant change minutes after
training has ended. The baseline changes that the au-
thors mention are not an issue according to our experi-
ence as they stayed stable across all 12 training sessions
in our protocol (cf. Fig. 2, Schabus, 2017). One can take
the alternative standpoint of Witte et al. (2018) that
NFT is just about ‘achieving an immediate regulation
ability’. Yet, would one then not still expect some
NFT-speciﬁc and objective changes in symptomatology
of the patients? For example, in our case changes in
some of the polysomnography-derived sleep quality or
memory-related measures.
Altogether, we agree with Witte and colleagues that well-
designed studies and standards are highly overdue.
However, in our opinion this is not limited to a lack of
standards for NFT data analysis but likewise for data ac-
quisition and speciﬁc NFT protocols applied to different
groups with different ‘outcome aims’. We appreciate that
Witte and colleagues openly discuss such important issues
and indeed present some ‘neuro’ data in their publications.
However, we widely disagree with their deﬁnition of ‘high
scientiﬁc standards’; especially in an area that is looked at
with so much doubt from scientists outside of their own
NFT in-group. In our view, many more rigorously con-
trolled and pre-registered studies (e.g. Schabus et al.,
2017; Schonenberg et al., 2017) as well as robust meta-
analyses (e.g. Sonuga-Barke et al., 2013; Cortese et al.,
2016) are needed if the ﬁeld ﬁnally strives to establish sci-
entiﬁc credibility for their method of choice.
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